Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD56-CAR T in Relapsed/Refractory NK/T Cell Lymphoma/Leukemia
NCT05941156Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD56 CAR T in Extranodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Overall Response Rate, Progression-Free Survival and 3 more. Started May 2023; status: recruiting.
02
Drugs
anti-CD56 CAR T
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on NCT05941156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941156.